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ABSTRACT
Objectives: To examine the great possibility that the indigenous black African man 
with prostate diseases requires a different diagnostic approach and strategies beyond 
the standard PSA reference levels generated in non-African study subjects. 
Design: A hospital based cross-sectional descriptive study.
Setting: The Urology Outpatient Clinic and Surgical Ward of Moi Teaching and Referral 
Hospital, Eldoret, Kenya between 1st April 2012 to 31st March 2013.
Subjects: Two hundred and nineteen patients aged 50 years and above with prostate 
diseases.
Main Outcome Measures: The main outcome measure was the PSA levels in patients 
diagnosed with Acute Prostatitis, Benign Prostate Hyperplasia (BPH) and Prostate 
Cancer in MTRH. The secondary outcome measures were the correlates associated 
with elevated PSA.
Results: Patients ranged in age from 50 to 96 years with a mean ± standard deviation 
of 65.4 ± 10.2 years. Clinical diagnosis of Acute Prostatitis, BPH and Prostate Cancer 
was made in 1.8, 63.9 and 34.3% of the study subjects respectively. Sixty-two patients 
(28.3%) had PSA in the laboratory reference range of 0-4ng/ml considered normal with 
an average of 1.8 ng/ml. The overall mean was 31.2 ng/ml and those with elevated 
PSA levels had a mean of 42.3 ng/ml. There was a positive correlate between prostate 
enlargement, urine retention, dysuria and family history of prostate disease and 
elevated PSA (all with p<0.001). 
Conclusions: The indigenous black African man has high levels of PSA even in 
benign prostate diseases. This together with histological findings of malignancy in 
some clinically diagnosed BPH with normal range PSA levels make the use of PSA 
in this group a bigger challenge. Studies should be conducted to not only elucidate 
the best use of PSA in the indigenous black African man but also his place in the new 
biomarkers to supplement or replace PSA in diagnosis and care.
INTRODUCTION
While evidence points to racial and geographical 
differences in the presentation of prostate diseases 
(1), much of the available data has been gathered 
from European and American studies and may 
not comprehensively address the problem among 
indigenous African population (2, 3). Efforts to 
diversify the use of PSA in terms of density and 
velocity have not shown greater reliability in 
diagnosis or prognostication of prostate malignancy 
(4). Emphasis is now on age and race specific 
ranges, the free to total PSA ratio, Prostate Specific 
Membrane Antigen and use of other biomarkers that 
can help distinguish benign from malignant prostate 
conditions.  The African American, the better studied 
of the African lineage, has been found to have 1.6 
times the risk of being diagnosed with prostate cancer 
and 2.4 times the risk of dying of it compared to his 
Caucasian counterpart (4). The fate of indigenous 
black Africans remains known only by default in a 
setting of unreliable, non-disease specific PSA (5-7). It, 
therefore, would be of great benefit while grappling 
with the treacherous and controversial topic of PSA 
and prostate diseases to have data on the indigenous 
black African man as this data is sorely missing. This 
study shares findings that suggest a peculiar position 
occupied by the indigenous black African man with 
regard to PSA and calls for greater research and data 
on how best to benefit from PSA, its components and 
other biomarkers in the diagnosis and interventional 
outcomes of prostate diseases.
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MATERIALS AND METHOD
Patients of indigenous black African extraction 
based on birth and exclusive residence in Africa 
presenting to the urology clinic or admitted with 
lower urinary tract symptoms ascribable to the 
prostate and diagnosed to have Acute Prostatitis, 
Benign Prostate Hyperplasia (BPH) or Prostate Cancer 
in the one year period of study (1st April 2012 to 31st 
March 2013) had their demographic data taken after 
formally consenting to participate in the study. Those 
with concomitant urethral strictures or considered 
to have other non-prostatic causes of bladder outlet 
obstruction were excluded. Clinical assessment 
included standard physical examination with a 
focused Digital Rectal Examination (DRE). Clinical 
diagnosis of Prostatitis was limited to the acute form 
and based on findings of a tender prostate with 
features of an acute inflammatory process. Benign 
Prostate Hyperplasia was considered where the 
examining urologist made findings in keeping with 
a benign prostate enlargement with no asymmetry 
or nodulations and having freely mobile overlying 
mucosa. Blood samples for the Prostate Specific 
Antigen (PSA) levels were collected at the first point 
of contact in the urology clinic. They were analysed 
in the standard laboratory procedure using Abbott 
IMx assay with a 0-4ng/ml normal range within 24 
hours of submission of blood to the laboratory in plain 
specimen bottles. Patients who underwent prostate 
surgery or had a prostate biopsy taken on suspicion 
of malignancy had histological confirmation of the 
prostate disease. Data were ethically collected using 
a pre-designed data sheet, entered in a spreadsheet, 
confirmed for completeness, cleaned and then 
analysed using Statistical Package for Social Science 
(SPSS) version 17.0 with focus on the primary and 
secondary outcome measures. The findings were in 
descriptive terms and relied on measures of central 
tendency as well as measures of dispersion. Inferential 
statistics assumed a 95% confidence interval and 
statistical significance at values ≤ 0.05.  The findings 
are presented in tables and narratives. 
RESULTS 
A total of 262 patients were diagnosed during the 
period of study to have one of the three prostate 
diseases namely Acute Prostatitis, BPH and Prostate 
Cancer. Forty-three patients with either associated 
urethral strictures independent of prostatic stenosis 
or suspected neurogenic bladder besides prostate 
enlargement were excluded from the study.
 The 219 patients recruited into the study were 
163 inpatients (74.4%) and 56 outpatients. The age 
range was between 50 and 96 years with a mean ± 
standard deviation of 65.4 ± 10.2 years. Table 1. 
Table 1















As of the time of presentation, 149 patients (68%) 
had had a history of urine retention. One hundred 
had a history of urethral catheterisation but only 45 
had indwelling catheters as of the time of admission 
to the ward.  
 On digital rectal examination, 157 patients 
(71.7%) had abnormal findings characterised by 
enlargement of the prostate, hardness, nodularity, 
tenderness or immobility of the overlying mucosa. 
Clinical diagnosis of Acute Prostatitis was made in 
four, BPH in 140 and prostate cancer in 75 patients, 
giving disease prevalence of 1.8%, 63.9% and 34.3% 
respectively. 
Sixty patients underwent surgery for obstructive 
prostate, 41 of whom had Trans-Urethral Resection 
of Prostate (TURP) while the rest had retro-pubic 
prostatectomy. 
 The 219 study subjects had a mean PSA level of 
31.2ng/ml.  Only 62 patients (28.3%) had PSA within 
the laboratory- referenced normal range of 0-4ng/ml. 
These patients had an average of 1.8 ng/ml. Those 
with elevated PSA levels had a mean of 42.3ng/ml. 
Table 2.
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Table 2
Distribution of PSA levels among prostate diseases
Disease PSA≤4ng/ml PSA>4ng/ml Total 
Ca Prostate 14(18.7%) 61(81.3%) 75
BPH 46(32.9%) 94(67.1%) 140
Prostatitis 2(50%) 2(50%) 4
Total 62(41.6%) 157(58.4%) 219
In the two diseases of surgical significance namely 
BPH and Prostate Cancer, BPH predominated in both 
categories of ≤4ng/ml and >4ng/ml in ratios of 3.3:1 
and 1.5:1 respectively. It, however, had PSA levels 
between 2 and 15 ng/ml. The odd ratio for BPH to 
be in the normal range was 2.0 while cancer of the 
prostate had a 1.7 odd ratio for elevated PSA. Seven 
patients clinically diagnosed as BPH had histological 
findings of malignancy and two of them had PSA in 
the given normal range of 0-4 ng/ml.
 Gross prostate enlargement on DRE was found 
to positively correlate with elevated PSA levels 
(p<0.001) as did a rise in age (p=0.041) with the 
highest levels being seen in the aged 70-79 years. 
Patients younger than 70 years had PSA in the range 
of 2-40ng/ml and histologically had 65.2% of BPH 
findings. Those older than 70 years predominated 
PSA levels in excess of 20 ng/ml and had 80% of the 
Prostate Cancer on histology. Urine retention, burning 
sensation on urination and family history of prostate 
disease all had highly significant correlations with 
elevated PSA (p<0.001). On multivariate analysis, 
urine retention and family history were found to be 
independent predictors of elevated PSA at p=0.002 
and 0.004 respectively.  
DISCUSSION 
The use of PSA in testing prostate diseases has been 
since 1987 but its usefulness in determining diagnosis, 
level of care and prognosis has remained controversial 
with up to 75% false positives and no single cut off 
point separating men with prostate cancer and benign 
pathologies (5, 8). African men have up to 15% higher 
PSA levels (9) and this has nothing to do with size 
or weight of his prostate (10).  Depressingly, there is 
literary no data on the indigenous black African and 
how he fits in the mix. This study makes efforts to 
utilise clinical and laboratory data to gain a glimpse 
into the magnitude of the challenge. In keeping 
with data on the African American, the PSA levels 
are significantly high with only 28.3% fitting in the 
normal range of 0-4 ng/ml. It was also evident that 
our PSA levels are significantly higher with clinically 
diagnosed BPH having PSA in excess of 10 ng/ml. 
This scenario is complicated by the finding that up to 
5% of those considered benign clinically turned out to 
have malignancy on histology; a  figure higher than 
that in studies done in America that have a range of 
2-4% (4). The overall mean of 31.2 ng/ml is in the 
realm of metastatic disease in most of the literature. 
This suggests, and is evident in the study findings, 
that even for the benign conditions, the indigenous 
black African man has significantly high levels of PSA. 
 There has existed a concern that reliance on PSA 
has led to unacceptable high level of over-diagnosed 
prostate cancer (11). This gets more complicated when, 
as in our study, some men in the range considered to 
be normal are found histologically to have malignancy. 
Ganna et al found Prostate Intraepithelial Neoplasia 
(PIN) to be a risk factor for malignancy independent 
of PSA 12 and since it precedes the disease by five 
to ten years, this has been considered a plausible 
explanation for the normal PSA with prostate cancer. 
The indigenous experience with this phenomenon 
is yet to fully unfold and remains an area in need of 
research. 
 The variability of PSA makes it difficult to 
draw conclusions on disease conditions and efforts 
have been made to diversify into its density and 
velocity but these additions are no better than total 
PSA in diagnosis and prognosis (4). The use of other 
kallikreins like human kallikrein peptidase (hK2) and 
cytokines like Interleukin-6(IL-6) and Transforming 
Growth Factor-beta1 (TGF-β1) have been billed as 
possible enhancers of the diagnostic and prognostic 
values of PSA (8).  We have no data on studies 
contacted in indigenous black Africans with regard 
to this new endeavour aimed at enhancing diagnosis 
and prognosis of prostate malignancy and it would 
be important if research in this aspect is done.  
 Inflammation is a key factor in prostate diseases 
(1) and this can explain our finding that patients 
with history of urine retention and dysuria tended to 
have higher PSA levels. A family history of prostate 
malignancy is an established risk factor for prostate 
cancer (5-7) and our finding it to be an independent 
predictor of higher PSA levels can be seen in this 
perspective.
 The findings on the rise  in PSA with an increase 
in age is in keeping with studies done elsewhere (7-9) 
and affords us the understanding that even among the 
indigenous black African men , this concept obtains 
but with higher figures.  For a group of people yet to 
get a footing on how their prostate problems relate 
to PSA, this can be a good starting point.
In conclusion, the indigenous black African man has 
high levels of PSA even in benign prostate diseases. 
This together with histological findings of malignancy 
in some clinically diagnosed BPH with normal range 
PSA levels make the use of PSA in this group a bigger 
challenge. We recommend that, studies should be 
conducted to not only elucidate the best use of PSA 
in the indigenous black African man but also his place 
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in the new biomarkers to supplement or replace PSA 
in diagnosis and care.
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